Evolving Regulatory Environment Could Bolster Biotech
July 01, 2021 at 11:00 AM EDT
The Food & Drug Administration’s (FDA) recent green light of Biogen’s Alzheimer’s disease drug Aducanumab – the first new Alzheimer’s approval in roughly two decades – could be a sign the FDA is taking a new approach to approvals.